NCT04439292 2026-03-18Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)National Cancer Institute (NCI)Phase 2 Active not recruiting35 enrolled
NCT03091257 2026-03-13A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple MyelomaMassachusetts General HospitalPhase 1 Active not recruiting30 enrolled